Modafinil: The Complete Australian Drug Profile
Last updated:
At a Glance
We compiled every clinically relevant data point on Modafinil into a single reference page — pharmacology, dosing, metabolism, interactions, side-effect incidence, and Australian regulatory status. This is not a sales pitch; it is a drug profile. Use it to have an informed conversation with your prescriber.
Mechanism of Action
Modafinil's exact mechanism has not been fully resolved, but converging evidence points to action across four neurotransmitter systems. Understanding these pathways explains why Modafinil feels different from caffeine or amphetamines:
| Pathway | Action | Functional Result |
|---|---|---|
| Dopamine | Inhibits dopamine transporter (DAT) reuptake | Improved motivation and reward processing |
| Norepinephrine | Increases noradrenergic activity | Heightened alertness and attention |
| Histamine | Activates tuberomammillary nucleus | Sustained wakefulness signal |
| Orexin/Hypocretin | Activates lateral hypothalamic neurons | Circadian-override wakefulness |
Unlike amphetamines (which flood dopamine receptors indiscriminately), Modafinil achieves wakefulness through targeted, lower-magnitude modulation. This is why it delivers focus without euphoria, appetite suppression without significant anorexia, and alertness without the "wired" jittery state.
Pharmacokinetic Profile
| Oral bioavailability | ~80 %; food does not significantly alter absorption |
| Tmax (peak plasma) | 2–4 hours after oral dose |
| Effective duration | 10–15 hours (dose-dependent) |
| Elimination half-life | 12–15 hours |
| Primary metabolism | Hepatic — CYP3A4 (major), amide hydrolysis |
| Enzyme induction | Mild CYP3A4 inducer; inhibits CYP2C19 |
| Excretion | Renal (80 % as metabolites, <10 % unchanged) |
TGA-Approved Indications
The Therapeutic Goods Administration has approved Modafinil for three clinical indications in Australia:
- Narcolepsy: First-line treatment for excessive daytime sleepiness (PBS listed)
- Shift Work Sleep Disorder: Improving wakefulness in patients with diagnosed SWSD
- Obstructive Sleep Apnoea (adjunct): As an add-on to CPAP therapy when residual EDS persists
Dosing Table
| Indication / Population | Dose | Timing |
|---|---|---|
| Narcolepsy / OSA | 200 mg once daily | Morning |
| Shift Work Sleep Disorder | 200 mg once | ~1 hr before shift |
| Hepatic impairment | 100 mg daily | Morning |
| Elderly patients | 100 mg daily (start) | Morning |
| Renal impairment | No adjustment (monitor) | Morning |
Some prescribers trial doses up to 400 mg/day, but published evidence does not demonstrate significantly greater wakefulness benefit above 200 mg. The additional dose primarily increases side-effect incidence.
Side-Effect Incidence Data
Common (≥10 % of patients in clinical trials)
- Headache (34 % — predominantly dehydration-related)
- Nausea (11 %)
Uncommon (1–10 %)
- Insomnia (5 % — dose-timing dependent)
- Decreased appetite (4 %)
- Dry mouth (4 %)
- Dizziness (3 %)
- Anxiety or nervousness (3 %)
- Diarrhoea (2 %)
- Rhinitis (2 %)
Rare but Serious (<0.1 %)
- Stevens-Johnson Syndrome: Extremely rare mucocutaneous reaction. Discontinue immediately at first sign of rash, blistering, or mucosal lesions. Seek emergency care.
- Angioedema: Swelling of face, lips, tongue, or throat. Requires immediate medical attention.
- Psychiatric effects: Hallucinations, mania, or suicidal ideation in extremely rare cases. Discontinue and consult prescriber.
Drug Interaction Matrix
Modafinil is metabolised by CYP3A4, mildly induces CYP3A4, and inhibits CYP2C19. This creates a specific interaction profile:
| Drug / Class | Interaction | Action Required |
|---|---|---|
| Hormonal contraceptives | CYP3A4 induction may ↓ efficacy | Use alternative/additional contraception |
| Warfarin | CYP2C19 inhibition may ↑ warfarin levels | Monitor INR closely |
| Cyclosporine | CYP3A4 induction may ↓ cyclosporine levels | Monitor blood levels, adjust dose |
| Ketoconazole / Itraconazole | CYP3A4 inhibition may ↑ Modafinil levels | Reduce Modafinil dose if needed |
| Carbamazepine / Rifampicin | CYP3A4 induction may ↓ Modafinil efficacy | May need higher Modafinil dose |
Absolute Contraindications
- Known hypersensitivity to Modafinil or Armodafinil
- History of SJS or toxic epidermal necrolysis
- Pregnancy and breastfeeding (TGA Category B3 — use with caution only if benefit outweighs risk)
- Severe hepatic impairment
- Uncontrolled moderate-to-severe hypertension or clinically significant arrhythmia
Australian Regulatory Status
Modafinil is classified as a Schedule 4 Prescription Only Medicine under the SUSMP (Standard for the Uniform Scheduling of Medicines and Poisons). A valid prescription from a registered medical practitioner is required.
PBS reimbursement is available for narcolepsy under the Authority Required programme. Off-label prescribing (e.g., for shift-work fatigue, ADHD adjunct) is at the prescriber's discretion and is not PBS-subsidised.
The TGA oversees manufacturing standards, importation, and supply chain integrity for all Modafinil products in Australia. Both Modalert (Sun Pharma) and Modvigil (HAB Pharma) are manufactured in WHO-GMP-certified facilities.
Storage Requirements
- Store below 25 °C in a cool, dry environment
- Protect from moisture and direct sunlight
- Keep in original blister pack until use
- Keep out of reach of children
- Do not use after the expiry date on the packaging
This drug profile is for informational purposes only and does not substitute for professional medical advice. Always consult your prescribing doctor or pharmacist for guidance tailored to your medical history. Data sourced from TGA-approved product information, published pharmacokinetic studies, and WHO reports. Current as of March 2026.
Compare Our Brands
Genuine Modalert and Modvigil with transparent per-tablet pricing. Price-beat guarantee on every order.
View Our Products